全文获取类型
收费全文 | 558篇 |
免费 | 46篇 |
国内免费 | 1篇 |
出版年
2021年 | 8篇 |
2020年 | 3篇 |
2018年 | 6篇 |
2017年 | 4篇 |
2016年 | 7篇 |
2015年 | 12篇 |
2014年 | 16篇 |
2013年 | 13篇 |
2012年 | 25篇 |
2011年 | 21篇 |
2010年 | 12篇 |
2009年 | 10篇 |
2008年 | 24篇 |
2007年 | 19篇 |
2006年 | 23篇 |
2005年 | 28篇 |
2004年 | 25篇 |
2003年 | 27篇 |
2002年 | 19篇 |
2001年 | 23篇 |
2000年 | 18篇 |
1999年 | 17篇 |
1998年 | 6篇 |
1997年 | 10篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 5篇 |
1993年 | 15篇 |
1992年 | 8篇 |
1991年 | 10篇 |
1990年 | 11篇 |
1989年 | 14篇 |
1988年 | 13篇 |
1987年 | 17篇 |
1986年 | 18篇 |
1985年 | 14篇 |
1984年 | 15篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1976年 | 3篇 |
1975年 | 5篇 |
1973年 | 6篇 |
1972年 | 5篇 |
1971年 | 2篇 |
1970年 | 3篇 |
1969年 | 5篇 |
1968年 | 3篇 |
排序方式: 共有605条查询结果,搜索用时 15 毫秒
601.
Maribeth Laude Katherine L. Russo Margalit B. Mokyr Sheldon Dray 《Cancer immunology, immunotherapy : CII》1993,36(4):229-236
We show here that in contrast to BALB/c mice bearing a late-stage, large MOPC-315 plasmacytoma, BALB/c mice bearing a late-stage, large RPC-5 plasmacytoma were not cured by cyclophosphamide therapy (15, 50, 100 or 200 mg/kg). However, most BALB/c mice bearing a late-stage RPC-5 tumor were cured by cyclophosphamide therapy (100 mg/kg) in conjunction with adoptive immunotherapy using tumor-infiltrated spleen cells (TISpC) that had been cultured with inactivated RPC-5 tumor cells plus polyethylene glycol 6000, even though this protocol was not effective for the therapy of mice bearing a barely palpable, early-stage RPC-5 tumor. Only a few of the mice that were cured of a late-stage RPC-5 tumor following adoptive chemoimmunotherapy (ACIT) were resistant to a subsequent challenge with RPC-5 tumor cells. However, the challenged mice that had developed progressively growing tumors could then be cured by cyclophosphamide alone when the tumor became large, even though this treatment was not curative for mice bearing a tumor of similar size but not previously treated by ACIT. Thus, the cure by ACIT of BALB/c mice bearing a lethal, late-stage RPC-5 tumor with extensive metastases provides a novel experimental tumor model for investigating the mechanisms by which a chemotherapeutic drug and adoptive cellular immunotherapy can cooperate in causing the complete regression of a large tumor load.Supported by research grant CA-30088 from the National Cancer Institute and IM-435 from the American Cancer Society. M. B. M. was supported by Career Development Award CA-01350 from the National Cancer InstituteThis work is a partial fulfillment of the requirements for the Ph.D. degree 相似文献
602.
603.
Anne M. Gurnett James P. O'Connell David E. Harris Hermann Lehmann Kenneth A. Joysey Eviatar Nevo 《Journal of Protein Chemistry》1984,3(5-6):445-454
The primary sequences of the myoglobins of two rodents (the South American viscacha and the Mediterranean mole rat) have been determined. Both myoglobins exhibit one polymorphism. The two rodent sequences have been compared with each other and with other known myoglobins. The myoglobin of the viscacha is similar to those of the diving mammals and penguin in having a high arginine content. Among mammalian sequences, the arginines at positions 77 (in one of the viscacha myoglobins) and 79 have been found only in the myoglobin from viscacha. Mole rat myoglobin has a lysine at position 31, where arginine or serine is found in all other known vertebrate myoglobins. 相似文献
604.
605.
Mary M. Bartik Barbara A. Baumgartel-Scofield Margalit B. Mokyr 《Cancer immunology, immunotherapy : CII》1991,34(2):79-89
Summary We have previously shown that thymocytes from low-dose melphalan (l-phenylalanine mustard)-treated MOPC-315-tumor-bearing mice (melphalan TuB) are able to generate an enhanced level of anti-MOPC-315 cytotoxicity, as compared to thymocytes from untreated MOPC-315-tumor-bearing mice or thymocytes from untreated or low-dose melphalan-treated normal mice, upon in vitro stimulation with MOPC-315 tumor cells in the presence of a low concentration of recombinant interleukin-2 (rIL-2). Here we show that the generation of enhanced anti-MOPC-315 cytotoxicity by melphalan TuB thymocytes depends on the ability of the thymocytes to proliferate. In addition, the ability of melphalan TuB thymocytes to generate an enhanced level of anti-MOPC-315 cytotoxicity correlated with their ability to proliferate more readily than thymocytes from untreated tumor-bearing mice and thymocytes from untreated or melphalan-treated normal mice in response to stimulation with MOPC-315 tumor cells plus a low concentration of rIL-2. Moreover, although fresh melphalan TuB thymocytes do not contain a higher percentage of phenotypically mature cells (i.e., CD4–/CD8+ or CD4+/CD8–) than do thymocytes from normal mice or untreated tumor-bearing mice, after a 5-day culture with both MOPC-315 tumor cells and a low concentration of rIL-2, cultures of thymocytes from melphalan TuB contained a much higher percentage of CD4–/CD8+ (but not CD4+/CD8–) cells than did cultures of thymocytes from the other two sources. Since CD4–/CD8+ cells were previously shown to be responsible for the exertion of antitumor cytotoxicity by thymocytes stimulated with MOPC-315 in vitro, our results indicate that the enhanced antitumor cytotoxicity exerted by melphalan TuB thymocytes following in vitro stimulation with MOPC-315 tumor cells in the presence of a low concentration of rIL-2 is due, at least in part, to an expansion of the pool of CD4–/CD8+ effector cells.Supported by research grant CA-35 761 from the National Cancer InstituteIn partial fulfillment of the requirements for the Doctor of Philosophy degreeSupported by career development award CA-01 350 from the National Cancer Institute 相似文献